Three Monthly Intravenous Injections of Ibandronate in the Treatment of Postmenopausal Osteoporosis
- 1 October 1997
- journal article
- clinical trial
- Published by Elsevier BV in American Journal Of Medicine
- Vol. 103 (4), 298-307
- https://doi.org/10.1016/s0002-9343(97)00249-0
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injectionJournal of Bone and Mineral Research, 1996
- A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogsJournal of Bone and Mineral Research, 1993
- Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosisJournal of Bone and Mineral Research, 1993
- Prevention and treatment of osteoporosis: A review of current modalitiesBone, 1992
- Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assayJournal of Bone and Mineral Research, 1992
- A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urineJournal of Bone and Mineral Research, 1992
- The Prevention and Treatment of OsteoporosisNew England Journal of Medicine, 1992
- BisphosphonatesDrugs, 1991
- BM 21.0955, a potent new bisphosphonate to inhibit bone resorptionJournal of Bone and Mineral Research, 1991
- Effect of Intermittent Cyclical Etidronate Therapy on Bone Mass and Fracture Rate in Women with Postmenopausal OsteoporosisNew England Journal of Medicine, 1990